Healthcare / BiotechnologyNasdaqGM
$17.25
+0.46 (+2.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-106.2M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$420M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.2%
↓Gross Margin
N/A
•Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+30.6%
FCF CAGR
—
FCF margin
-1827.4%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.7M · net income $-109.7M · FCF $-85.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.7M | $4.7M | $4.3M | $750000.00 | $2.1M |
| Net Income | $-109.7M | $-109.7M | $53.5M | $-65.7M | $-50.4M |
| EBITDA | $-61.8M | $-61.8M | $37.4M | $-17.7M | $-79.9M |
| EPS | -4.60 | -4.60 | 2.10 | -2.40 | -1.80 |
| Operating Margin | -2114.7% | -2114.7% | -3154.0% | -19493.5% | -9464.4% |
| Net Margin | -2355.4% | -2355.4% | 1240.1% | -8759.6% | -2409.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.05 | 0.05 | 0.09 |
| Current Ratio | 6.59 | 6.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-85.1M | $-85.1M | $-134.4M | $-106.2M | $-181.0M |
| Returns | |||||
| ROE | -35.2% | -35.2% | 12.9% | -14.2% | -9.3% |
| Valuation | |||||
| P/E | — | — | 8.95 | — | — |
| EV/EBITDA | — | — | 5.97 | — | — |
| P/B | 1.33 | 1.33 | 1.16 | 1.58 | 1.68 |
| Growth & Yield | |||||
| Revenue Growth | 8.0% | 8.0% | 475.3% | -64.1% | — |
| EPS Growth | -319.0% | -319.0% | 187.5% | -33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.8%
Start / end P/E
n/dx → n/dx
EPS bridge
2.10 → -4.60
Residual
+0.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.